<DOC>
	<DOCNO>NCT00002318</DOCNO>
	<brief_summary>To determine efficacy Stealth liposomal doxorubicin hydrochloride ( DOX-SL ) treatment severe AIDS-related Kaposi 's sarcoma ( KS ) comparison establish therapy ABV : Adriamycin ( doxorubicin ) /bleomycin/vincristine . To evaluate safety tolerance DOX-SL compare ABV population AIDS patient severe KS .</brief_summary>
	<brief_title>A Comparison DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine Treatment Severe AIDS-Related Kaposi 's Sarcoma</brief_title>
	<detailed_description>Patients randomize receive either DOX-SL ABV combination . Infusions give day 1 every 2 week total six cycle . Kaposi 's sarcoma lesion evaluate prior every cycle , end last treatment cycle , 4 week follow end last treatment . Patients must agree one representative KS lesion biopsied .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Prophylaxis PCP , cryptococcal , herpes infection , antiretroviral therapy ( e.g. , AZT , ddC , ddI ) provide dos stable least 1 month . Therapy tuberculosis , fungal , herpes infection except potentially myelotoxic chemotherapy . Foscarnet new episode cytomegalovirus infection . Colonystimulating factor erythropoietin . Patients must : Biopsyproven , progressive , AIDSrelated Kaposi 's sarcoma , follow : At least 25 mucocutaneous lesion . Ten new lesion prior month . Documented visceral disease least two accessible cutaneous lesion . Two accessible cutaneous lesion edema . Documented antiHIV antibody . No active opportunistic infection mycobacteria , cytomegalovirus , toxoplasma , Pneumocystis carinii , microorganism ( treatment myelotoxic drug ) . Life expectancy &gt; 4 month . NOTE : Patients respond therapy protocol , well fail ABV combination , eligible enter Liposome Technology open trial use DOXSL alone . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Clinically significant cardiac , hepatic , renal disease . Peripheral neuropathy , sign moderate severe sensory loss , moderate mark motor loss . Inability comply study . Concurrent Medication : Excluded : Other cytotoxic chemotherapy . Ganciclovir . Patients follow prior condition exclude : Prior neoplasms treat extensive chemotherapy , investigator 's opinion , lead irreversibly compromise bone marrow function . History idiosyncratic allergic reaction bleomycin vincristine . Prior Medication : Excluded : Prior anthracycline therapy . Cytotoxic chemotherapy interferon treatment within past 4 week . Prior Treatment : Excluded : Radiation electron beam therapy within past 3 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 1996</verification_date>
	<keyword>Vincristine</keyword>
	<keyword>Sarcoma , Kaposi</keyword>
	<keyword>Liposomes</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Bleomycin</keyword>
	<keyword>Drug Carriers</keyword>
</DOC>